Evidence map›Paper›PMID 37899396›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2023

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.

Xiaoyang Dai, Xiangning Liu, Fujing Ge, Hongdao Zhu, Churun Zheng, Fangjie Yan, Bo Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xiaoyang DaiCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. daixiaoyang@zju.edu.cn.
Xiangning LiuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. 22219086@zju.edu.cn.
Fujing GeCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Hongdao ZhuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Churun ZhengCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Fangjie YanInnovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China. 11719047@zju.edu.cn.
Bo YangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. yang924@zju.edu.cn.
Zhejiang University · CNZhejiang Lab · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the effects of PLK1 inhibitors on osimertinib-resistant non-small cell lung carcinoma (NSCLC) cells and the anti-tumor effect combined with osimertinib.

methodsAn osimertinib resistant NCI-H1975 cell line was induced by exposure to gradually increasing drug concentrations. Osimertinib-resistant cells were co-treated with compounds from classical tumor pathway inhibitor library and osimertinib to screen for compounds with synergistic effects with osimertinib. The Gene Set Enrichment Analysis (GSEA) was used to investigate the activated signaling pathways in osimertinib-resistant cells; sulforhodamine B (SRB) staining was used to investigate the effect of PLK1 inhibitors on osimertinib-resistant cells and the synergistic effect of PLK1 inhibitors combined with osimertinib.

resultsOsimertinib-resistance in NCI-H1975 cell (resistance index=43.45) was successfully established. The PLK1 inhibitors GSK 461364 and BI 2536 had synergistic effect with osimertinib. Compared with osimertinib-sensitive cells, PLK1 regulatory pathway and cell cycle pathway were significantly activated in osimertinib-resistant cells. In NSCLC patients with epidermal growth factor receptor mutations treated with osimertinib,

conclusionsPLK1 inhibitors have a synergistic effect with osimertinib on osimertinib-resistant NSCLC cells which indicates that they may have potential clinical value in the treatment of NSCLC patients with osimertinib resistance.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesAniline CompoundsBenzimidazolesCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsHumansIndolesMutationPyrimidinesThiophenesAcrylamidesAniline CompoundsBenzimidazolesErbB ReceptorsGSK 461364IndolesosimertinibPyrimidinesThiophenesBioinformaticsDrug combinationDrug resistanceNCI-H1975 cellsNon-small cell lung carcinomaOsimertinibPolo-like kinase1 inhibitors

Identifiers

PMID37899396
PMCPMC10630054
OpenAlexW4387764962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.